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Summary
Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within
the juxtamembrane domain of the FLT3 receptor, suggesting that it may be a target for kinase inhibitor therapy. For this
purpose we have developed CT53518, a potent antagonist that inhibits FLT3, platelet-derived growth factor receptor
(PDGFR), and c-Kit (IC50 200 nM), while other tyrosine or serine/threonine kinases were not significantly inhibited. In Ba/
F3 cells expressing different FLT3-ITD mutants, CT53518 inhibited IL-3-independent cell growth and FLT3-ITD autophos-
phorylation with an IC50 of 10–100 nM. In human FLT3-ITD-positive AML cell lines, CT53518 induced apoptosis and inhibited
FLT3-ITD phosphorylation, cellular proliferation, and signaling through the MAP kinase and PI3 kinase pathways. Therapeutic
efficacy of CT53518 was demonstrated both in a nude mouse model and in a murine bone marrow transplant model of
FLT3-ITD-induced disease.
Introduction tandem duplication (ITD) within the juxtamembrane domain,
and an additional 7% have a point mutation in the kinase acti-
vation loop (Abu-Duhier et al., 2001; Kiyoi et al., 1999; Kotta-Acute myelogenous leukemia (AML) is a clonal hematopoietic
stem cell disorder that increases in incidence with age and ridis et al., 2001; Nakao et al., 1996; Rombouts et al., 2000;
Whitman et al., 2001; Yamamoto et al., 2001; Yokota et al.,represents90% of all acute leukemias in adults (Lowenberg et
al., 1999). Although induction chemotherapy results in complete 1997). FLT3 is an attractive target for therapeutic intervention
as the single most commonly mutated gene in AML and becauseremission in 50%–75% percent of patients, relapse is common
and long-term survival rates remain at20%. Thus, more effec- FLT3 mutations confer a poor prognosis (Abu-Duhier et al.,
2000; Kiyoi et al., 1999; Kottaridis et al., 2001; Stirewalt et al.,tive treatment strategies are needed. Targeted inhibition of aber-
rant kinase signaling can be an effective therapeutic intervention 2001). We have developed CT53518, a potent FLT3 antagonist
of the piperazinyl quinazoline class that also inhibited PDGFRin hematologic malignancies, as evidenced by hematologic and
cytogenetic responses in chronic myelogenous leukemia (CML) and c-Kit but did not have significant activity against a wide
range of other kinases. CT53518 is a potent inhibitor of FLT3-and CML blast crisis patients treated with the BCR/ABL kinase
inhibitor STI571 (Carroll et al., 1997; Druker and Lydon, 2000; ITD-transformed hematopoietic cell lines and of human AML
cell lines expressing the mutant FLT3 receptor. In addition,Druker et al., 2001a, 2001b; Savage and Antman, 2002). An
analogous kinase inhibitor strategy may be useful in AML pa- CT53518 is a potent inhibitor in murine models of FLT3-ITD-
mediated disease. Taken together, these data indicate that, bytients with activating mutations in FLT3. The most common
FLT3 mutation, found in up to 30% of patients, is an internal analogy with activity of STI571 in CML blast crisis, CT53518
S I G N I F I C A N C E
Most adults who develop AML die from their disease or complications of cytotoxic chemotherapy. Constitutively activated FLT3
(FLT3-ITD) represents the single most common mutation in AML and confers a poor prognosis. FLT3-ITD is thus an attractive potential
therapeutic target for tyrosine kinase inhibition. We have developed CT53518, which selectively blocks FLT3-ITD phosphorylation,
leading to an inhibition of Erk2 and Akt signaling and to induction of apoptosis in FLT3-ITD-positive human AML cell lines. In animals,
CT53518 is orally bioavailable, has suitable pharmacokinetic and toxicity profiles for clinical use, and is efficacious in murine models
of FLT3-ITD-mediated disease. CT53518 may be a useful therapeutic agent in the treatment of FLT3-ITD-positive AML and is currently
under evaluation in clinical trials.
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Table 1. Specificity and potency of CT53518 kinase inhibitor
CT53518 Staurosporin
Receptor tyrosine kinases IC50 IC50












PKC, PKA 30 0.08
MAP kinases and MAPK kinases
Mek1, Mkk4, Mkk6, Erk2, p38 30 1
Autophosphorylation of all receptor tyrosine kinases were measured in in-
tact cells using a two-site enzyme-linked immunosorbent assay except for
InsR which, together with the cytoplasmic receptors, was assayed using
purified enzyme. See Experimental Procedures.
may have therapeutic value in AML associated with activating
mutations in FLT3.
Figure 1. Effect of CT53518 on ligand-stimulated and constitutive phosphory-
lation of FLT3Results
A: Chemical structure of CT53518. The chemical name is 4-[6-methoxy-
7-(3-piperidine-1-yl-propoxy)-quinazolin-4-yl]-piperazine-1-carboxylic acid
Selective kinase inhibition by CT53518 (4-isopropoxyphenyl) amide (MF  C31H42N6O4, MW  562.7).
Novel small molecule FLT3 kinase inhibitors of the piperazinyl B: Constitutive phosphorylation of FLT3-ITD mutants in Ba/F3 cells. Ba/F3 cells
expressing wild-type FLT3 (wt) or each of the five FLT3-ITD mutants (Npos,quinazoline class were identified by screening of chemical librar-
W51, W73, W78, and T6) were unstimulated () or stimulated () with 50ies. The specificity of an optimized analog, CT53518, was then
ng/ml of recombinant human FLT3 ligand (FL). Cell lysates were prepared
tested against a wide range of kinases. The relative kinase inhibi- and FLT3 protein was immunoprecipitated with anti-FLT3 polyclonal anti-
tory activity of CT53518 was first tested in the related type III body, resolved by SDS-PAGE, and immunoblotted with either anti-phospho-
tyrosine monoclonal antibody or anti-FLT3 polyclonal antibody, as indi-RTKs as previously described (Yu et al., 2001). CT53518 inhib-
cated.ited FLT3, PDGFR, and c-Kit with an IC50 of 170–220 nM in in C and D: CT53518 inhibits phosphorylation of wt FLT3 and FLT3-ITD in Ba/F3
vitro kinase assays, whereas 15- to 20-fold higher concentration cells. Ba/F3 cells expressing wt FLT3 (C) and W51 FLT3-ITD (D) were incubated
with the indicated concentrations of CT53518, and cells expressing wt FLT3was required to inhibit CSF-1R (Table 1). When similar cell-
were then unstimulated () or stimulated () with 100 ng/ml of FL. Cellbased assays for the FGFR, EGFR, and KDR receptor tyrosine
lysates were prepared and FLT3 protein was immunoprecipitated followed
kinases or purified enzyme assays for insulin receptor, cyto- by immunoblot analysis using either anti-phosphotyrosine monoclonal anti-
plasmic tyrosine kinases, serine/threonine kinases, or members body or anti-FLT3 polyclonal antibody as shown.
of the MAPK cascades were performed, no significant inhibition
was observed at 100-fold higher concentrations (Table 1). In
control experiments, staurosporin inhibited all kinases with an
to Ba/F3 cells, allowing the system to be used to study FLT3-IC50 of 1 M (Table 1). These studies demonstrated that
ITD-specific signaling. The level of receptor tyrosine phosphory-CT53518 is a potent and highly selective inhibitor of FLT3, c-Kit,
lation was measured in the absence or presence of 50 ng/mland PDGFR. Inhibition was reversible since PDGF-induced au-
FLT3 ligand (FL) (Figure 1B). FLT3 was immunoprecipitated fromtophosphorylation rapidly returned to pretreatment level follow-
cell lysates, proteins were separated by SDS-PAGE, and immu-ing withdrawal of CT53518 (data not shown).
noblot analyses were performed using anti-phosphotyrosine
monoclonal antibody PY99 or anti-FLT3 polyclonal antibody.
CT53518 inhibits FLT3-ITD autophosphorylation All five FLT3-ITDs exhibited a high level of autophosphorylation
and mitogenic signaling in Ba/F3 cells with little augmentation by addition of FL, whereas autophosph-
We next tested the ability of CT53518 to inhibit constitutively orylation of wild-type FLT3 was only observed upon ligand stim-
activated FLT3-ITD mutants cloned from AML patients (W51, ulation (Figure 1B). To examine the inhibitory activity of CT53518
W73, W78, Npos, and T6) (Kelly et al., 2002). Stable expression against FLT3-ITDs, Ba/F3 cells expressing the W51 mutant were
incubated with various concentrations of CT53518 (0.003–3M)of each of these five cDNAs confers IL-3-independent growth
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Figure 2. CT53518 inhibits FLT3-ITD-induced prolif-
eration and intracellular signaling in AML cell lines
A: FLT3 receptor levels in leukemia cell lines. Cell
lysates from 5  105 or 10  105 cells of leukemia
cell lines Molm-14, Molm-13, RS4;11, THP-1, and
KG-1 were prepared, subjected to SDS-PAGE
analysis, and immunoblotted with anti-FLT3 poly-
clonal antibody. Shown is a representative blot
of three separate experiments.
B: FLT3 tyrosine phosphorylation in leukemia cell
lines. Molm-14, Molm-13, RS4;11, THP-1, and KG-1
leukemia cells were either unstimulated () or
stimulated () with 100 ng/ml of FL and cell ly-
sates were prepared. FLT3 protein was immu-
noprecipitated followed by immunoblot analy-
sis using an anti-phosphotyrosine monoclonal
antibody.
C: Effect of CT53518 on tyrosine phosphorylation
of FLT3-ITD in Molm-14 AML cells. Molm-14 cells
were incubated with indicated concentrations
of CT53518 and cell lysates were prepared. FLT3
protein was immunoprecipitated followed by im-
munoblot analysis using anti-phosphotyrosine
monoclonal antibody or anti-FLT3 polyclonal an-
tibody as indicated.
D: CT53518 inhibits proliferation of AML cells ex-
pressing FLT3-ITD. We plated 3  104 of the indi-
cated leukemia cells in 1 ml of culture media
in the presence of increasing concentrations of
CT53518 (0.004–30 M). Cells were grown for 3
days in tissue culture and viable cells were
counted. Shown are representative growth
curves of three independent experiments.
E and F: CT53518 inhibits Erk and Akt phosphoryla-
tion in FLT3-ITD-positive AML cells. Molm-14 and
THP-1 AML cells were incubated with indicated
concentrations of CT53518. Cell lysates were pre-
pared and resolved on SDS-PAGE followed by
immunoblot analysis using anti-phospho-Erk2 or
anti-phospho-Akt1 as well as anti-Erk and anti-
Akt antibodies as indicated. FL-stimulated con-
trol sample shown in F.
prior to cell lysis. As a comparison, the same experiments were higher concentrations of CT53518 were required to cause non-
specific toxicity (data not shown). CT53518 inhibition of prolifer-performed with cells expressing wild-type FLT3 that were stimu-
lated with FL. CT53518 inhibited wild-type FLT3 or W51 tyrosine ation was also evaluated in Ba/F3 cells transformed to IL-3-
independent growth by TEL/PDGFR, TEL/TRKC, or BCR/ABL,phosphorylation with an IC50 of 30–100 nM (Figures 1C and 1D).
Similar results were obtained with Ba/F3 cells expressing Npos respectively. CT53518 effectively inhibited growth of TEL/
PDGFR transformed cells at 30 nM when compared to un-and T6 FLT3-ITDs (data not shown).
To determine the effect of CT53518 on FLT3-ITD-mediated treated cells or cells transformed with BCR/ABL or TEL/TRKc
(Table 2). These data further confirm the inhibition of the typecell growth, Ba/F3 cells expressing each mutant were grown
in increasing concentrations of inhibitor and viable cells were III RTKs (including PDGFR, KIT, and c-FMS) by CT53518 and
the lack of inhibition of other tyrosine kinases including ABLcounted 3 days later. In the absence of CT53518, the number
of cells increased 5- to 10-fold, and this growth was inhibited and TRKc. This result also indicates that nonspecific cytotoxic
effects are not observed within the effective range of drug con-by CT53518 with IC50 values of 10–30 nM (Table 2). Inhibition
was specific for FLT3-ITD-mediated cell growth since the centration. It should be noted that the IC50 values for growth
inhibition were approximately 20- to 50-fold lower in Ba/F3 cellsgrowth inhibition could be rescued with IL-3, and 1000-fold
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Oetzel et al., 2000). To explore the possibility that FLT3-ITDTable 2. CT53518 inhibits FLT3/ITD-mediated Ba/F3 cell proliferation
signaling plays a similar role in AML cells, Molm, THP-1, KG-1,Cell Line IC50 (M)
and RS4;11 cells were incubated with increasing concentrations
WT ND of CT53518 (0.004–30 M) and cell growth was monitored.
T6 0.01
CT53518 inhibited cell proliferation of the FLT3-ITD-positiveNpos 0.02
Molm-13 and Molm-14 with an IC50 of 10 nM, whereas theW73 0.03
W78 0.02 FLT3-ITD-negative THP-1, KG-1, and RS4;11 cells were highly
W51 0.02 resistant, requiring 1000-fold higher concentrations to inhibit
TEL/PDGFR 0.02 cell growth (Figure 2D).TEL/TRKC 2.00
For the other type III RTK family members, the MAP kinase,BCR/ABL 25.0
PI-3 kinase, Src kinase, and STAT pathways play an important
Cells (3  104) were grown in medium without IL-3 and in the presence
role in oncogenic transformation, but the role of these pathwaysof increasing concentrations of CT53518 (0.004–30 M). Viable cells were
in FLT3-ITD signaling in AML cells is less well characterizedcounted after 3 days and the concentration of CT53518 that inhibits 50%
growth was determined. Shown are representative data from three inde- (Birkenkamp et al., 2001; Iida et al., 1999; Towatari et al., 1997).
pendent experiments. Since FLT3-ITD signaling is required for Molm-14 AML cell
growth and survival, selective inhibition by CT53518 was utilized
to investigate the role of the MAP and PI-3 kinase pathways.
As a measurement of MAP kinase signaling, the level of Erk2
phosphorylation was determined by Western blot analysis ofthan the level required for FLT3 enzyme inhibition in CHO cells
Molm-14 cells following incubation with increasing concentra-(Figure 1D) and may reflect the low levels of FLT3 expression
tions of CT53518 (0.003–3 M). A high level of constitutive Erk2in Ba/F3 cells.
phosphorylation was observed in Molm-14 cells that could be
completely inhibited by 300 nM CT53518 (Figure 2E). Similarly,Role of FLT3-ITD signaling in human leukemia cells
high levels of phospho-Erk2 were detected in THP-1 cells, butTo extend these studies to a more clinically relevant system,
treatment with CT53518 at concentrations up to 3 M hadthe effect of CT53518 inhibition of FLT3 on the growth and
little or no effect on Erk2 phosphorylation (Figure 2E). RTKssurvival of human leukemia cell lines was examined. FLT3 RNA
commonly utilize the PI-3 kinase pathway to promote cell sur-was detected in the leukemia cell lines KG-1, RS4;11, THP-1,
vival through recruitment of Akt to the plasma membrane, re-Molm-13, and Molm-14 cells (Matsuo et al., 1997; Yokota et
sulting in its activation by phosphorylation (Blume-Jensen andal., 1997) using Taqman analysis (data not shown). By Western
Hunter, 2001; Stephens et al., 1998; Stokoe et al., 1997). There-blot analysis, Molm-14 and RS4;11 had the highest level of
fore, anti-phospho-Akt Western blot analysis was performed onFLT3 expression. THP-1 had an intermediate level, whereas 10-
Molm-14 cells to assess the level of Akt phosphorylation as ato 20-fold less FLT3 expression was observed in Molm-13 and
measurement of PI-3 kinase pathway activation. As with Erk2,KG-1 (Figure 2A). Quantitative measurement of FLT3 protein
a constitutively high level of Akt phosphorylation was readilyestimated a range of 1,000–10,000 receptors per cell (data not
detected and was efficiently blocked by pretreatment of theshown). Previous screening of leukemia cell lines for FLT3-ITD
Molm-14 cells with 100–300 nM CT53518 (Figure 2F). THP-1mutations identified a 7 codon ITD in Molm-13, but the effect
cells also showed constitutive Akt phosphorylation, but this wasof this mutation on receptor phosphorylation and signaling was
unaffected by treatment with CT53518 at concentrations up tonot determined (Yokota et al., 1997). Sequence analysis re-
10 M.vealed that the FLT3-ITD in Molm-13 and Molm-14 contained
To determine if inhibition of Molm cell proliferation was ac-an additional phe codon at the 5	 end of a 6 codon ITD (DFREYE,
companied by apoptosis, annexin-V binding was monitored byamino acids 593–598) (data not shown). Both Molm cells also
flow cytometry. Treatment of FLT3-ITD-positive Molm-14 cellsexpressed wild-type FLT3, while there were no FLT3-ITD muta-
with CT53518 resulted in an increase in the percentage oftions found in THP-1, KG-1, or RS4;11. To evaluate the level
annexin-V binding cells from a background level of 5% to 51%of FLT3 activation in these leukemia cell lines, FLT3 autophos-
at 24 hr and 78% at 96 hr (Figure 3). As expected, CT53518phorylation was measured using anti-phosphotyrosine Western
treatment of FLT3-ITD-negative THP-1 cells had no effect onblot analysis. Ligand-independent FLT3 phosphorylation was
annexin-V binding. To further demonstrate that the induction ofobserved in Molm-13 and Molm-14, whereas FLT3 phosphory-
apoptosis by CT53518 was due to FLT3 inhibition, treatmentlation in THP-1, KG-1, and RS4;11 cells was only seen following
of Molm-14 cells with STI571, which inhibits c-Kit and PDGFRFL stimulation (Figure 2B). There was, however, significant stim-
but not FLT3, had no affect on annexin-V binding (Figure 3).ulation of autophosphorylation by FL in the Molm-13 and Molm-
These results established that FLT3-ITD-activated cellular sig-14 cells lines, which may be due to further stimulation of the
naling pathways are essential for these AML cell lines prolifera-FLT3-ITD allele, or stimulation of wild-type FLT3 receptor in
tion and survival.these cells. More importantly, pretreatment of Molm 14 with
CT53518 inhibited the constitutive FLT3-ITD phosphorylation
Evaluation of CT53518 in vivo in a nude mouse modelwith an IC50 of 30 nM (Figure 2C). These studies demonstrate
We first tested the efficacy of CT53518 in a murine model inthat the endogenous FLT3-ITD expressed in Molm cells is acti-
which FLT3-ITD-transformed Ba/F3 cells were injected intovated but can be selectively inhibited by CT53518.
nude mice resulting in tumor development and death. As notedSTI571 treatment of myeloid or lymphoid cells that express
above, FLT3-ITD cDNAs cloned from patient AML samples wereBCR/ABL blocks proliferation and induces apoptosis, whereas
expressed in IL-3-dependent Ba/F3 cells. Although these cellsPhiladelphia chromosome (Ph)-negative leukemia cells are unaf-
fected (Beran et al., 1998; Druker et al., 1996; Fang et al., 2000; no longer require IL-3 for growth, their proliferation and survival
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Figure 3. CT53518 induces apoptosis in FLT3-ITD-positive AML cells
Molm-14 and THP-1 AML cells were cultured in growth medium in the presence of 1 M CT53518 or 3 M STI571. Cells were harvested daily and stained
with annexin V-FITC and propidium iodide followed by flow cytometric analysis. Total percentage of annexin V-positive cells is shown on top of each
diagram. Shown are representative data from three independent experiments.
was dependent on FLT3-ITD signaling that was inhibited by using a murine bone marrow transplant (BMT) assay for FLT3-
CT53518 with an IC50 of 10–30 nM (Table 2). To evaluate the in ITD-induced myeloproliferative disease (Kelly et al., 2002). To
vivo efficacy of CT53518, 20 female athymic nude (nu/nu) mice best mirror a human treatment regimen, we chose to assess
were injected via tail vein with 1  106 W51 cells, and the efficacy of CT53518 in established disease. Our previous obser-
animals were divided into treatment and vehicle control groups vations with the FLT3-ITD BMT assay indicated that disease
(n  10/group). Starting on day 7 postinoculum, CT53518 was was well established at approximately 30 days posttransplant
administered by oral gavage at 60 mg/kg bid until day 42, and that 90% of animals succumbed to disease by day 60
whereas the control group received the 0.5% methylcellulose (Kelly et al., 2002). Moribund mice with splenomegaly were
vehicle only. Mortality of 100% was observed by day 40 for the sacrificed during the trial and all remaining mice were sacrificed
vehicle control group, whereas CT53518 treatment caused a at trial endpoint. Three independent trials were performed and
statistically significant (p  0.001 by a log rank test) increase involved a total of 35 placebo and 33 drug-treated animals. In
in survival that was extended on average by 20 days (Figure trial 1, mice were treated with drug from day 32; in trials 2 and
4A). In a second study, animals were dosed under the same 3, drug was administered from day 25.
protocol at either 60 mg/kg bid or 20 mg/kg bid. When compared
to vehicle controls, a significant (p  0.05) increase in survival Characterization of the pharmacokinetic properties
was observed at both doses with a 10% or 20% cure rate at
of CT53518 in Balb/c micethe low and high doses, respectively (Figure 4B). Monitoring
Pharmacokinetic properties of CT53518 were evaluated in 27of CT53518 levels determined that the average nadir plasma
Balb/c mice dosed by oral gavage at 60 mg/kg, and serialconcentration (66 nM) may not have been sufficient to com-
plasma samples were collected for determination of compoundpletely block FLT3 throughout the dosing period and suggest
concentrations. Following gavage, a peak plasma concentrationthat optimal responses may require higher dose levels in this
of 3.3 M was observed at 1 hr and the estimated terminalmurine model (data not shown).
phase half-life was 2.87 hr (Figure 5E). At 10 hr after dosing,
plasma concentrations were 200 nM approaching the IC90 ofIn vivo efficacy of CT53518 in a bone marrow
300 nM, indicating that adequate drug coverage could betransplant model of FLT3-ITD-induced
achieved with bid dosing. On the last day of trial 2, 2–3 animalsmyeloproliferative disease
each in the drug-treated group were sacrificed at 2, 6, and 12We next tested in vivo efficacy of CT53518 in primary hemato-
poietic cells transformed by FLT3-ITD. Trials were performed hr post morning dose, and their plasma samples were taken to
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for placebo animals, corresponding to a 5-fold increase in size
compared to irradiated transplanted controls (100 mg). In con-
trast, CT53518-treated mice displayed only a slight increase in
median spleen weight (189 mg). Similarly, the median WBC
count for placebo animals was 23.0 106/ml compared to 4.3
106/ml for drug-treated animals. These results demonstrate that
mice treated with CT53518 had a markedly reduced disease
burden compared to untreated controls. It should be noted that
in each trial, at least one CT53518-treated mouse had all of the
manifestations of FLT3-ITD-induced MPD at study endpoint,
which may reflect slight variability in disease burden or body
weight in certain animals at onset of treatment.
For a subset of animals, WBC count was monitored at inter-
vals throughout trial 2 by retroorbital sampling. Results from
this analysis showed that total leukocyte counts from peripheral
blood were all above normal range at the onset of therapy (12
106/ml–33  106/ml) and decreased to the normal range with
therapy (Figure 6A) but not with placebo (Figure 6B), consistent
with activity of CT53518 in reducing the disease burden. Com-
parison of WBC differentials for the mice from all three trials
(Figure 6C) further demonstrated efficacy of CT53518 in treat-
ment of FLT3-ITD-induced MPD. Whereas a wild-type untrans-
planted BALB/c mouse had approximately 69% lymphocytes
and 23% neutrophils, the placebo mice with MPD had a reversal
in these proportions to 18% lymphocytes and 74% neutrophils,
reflecting a massive increase in myelopoiesis (Table 3). The
relative proportions of eosinophils, monocytes, and basophils
remained constant. In contrast, mice treated with CT53518
showed a normal total leukocyte count of 4.3 106/ml (Table 4),Figure 4. CT53518 treatment increases survival in a Ba/F3 nude mouse model
of FLT3-ITD-mediated leukemia with a reversion to lymphocyte predominance in the differential
Nude mice (n  10 for each CT53518-treated or vehicle control group) (56% lymphocytes and 36% neutrophils) (Figure 6C).
were each injected via tail vein with 1  106 Ba/F3 cells expressing W51 At the endpoint for trial 3, a subset of drug-treated animals
FLT3-ITD mutant. BID dosing via oral gavage was started on 7 days post cell without physical evidence of disease were removed from drug
injection in two separate studies with either vehicle or 60 mg/kg of CT53518
therapy and monitored for subsequent signs of disease. Aftersuspended in 0.5% methyl cellulose (A) or with either vehicle, 20 or 60 mg/
drug withdrawal, these animals developed classical FLT3-ITDkg of CT53518 (B). Dosing was terminated on 42 or 57 days post cell injection
as indicated. myeloproliferative disease with a median latency of 45 days
after cessation of drug (day 103) (Figure 6D; Kelly et al., 2002).
At the time of sacrifice, the WBC counts and spleen weights of
these animals (Table 3, trial 3) mirrored those for untreatedmeasure CT53518 concentration. The average plasma concen-
FLT3-ITD trial mice. These data suggest that the treatment regi-tration of CT53518 was 766 nM (431 ng/ml) at 2 hr, 361 nM
men carried out during this trial was not sufficient to eliminate all(203 ng/ml) at 6 hr, and 266 nM (150 ng/ml) at 12 hr (Figure
FLT3-ITD hematologic progenitor cells from the treated animals5F). In general, these steady-state concentrations were consis-
since removal of therapy results in the development of a MPD oftent with those obtained in the single-dose PK analysis and
similar latency and characteristics as that in untreated FLT3-ITD.were above the IC50 of CT53518 for FLT3. More detailed pharma-
Histopathologic examination of the spleen from representa-cokinetic studies were performed in dog and monkey in which
tive animals (Figure 6E) further supported the interpretation oforal bioavailability ranged from 50%–100% and the terminal
a dramatic reduction in MPD in the drug-treated mice comparedplasma half-life was 7–16 hr (data not shown).
to placebo controls. The drug-treated animals showed a partial
recovery of splenic architecture (Figure 6E, i), a reduction inOutcome of CT53518 trials in the murine
myeloid hyperplasia, and a corresponding increase in the pro-FLT3-ITD BMT model
portion of other hematopoietic lineages (Figure 6E, ii). TheseKaplan-Meier analyses for survival (Figures 5A–5C) of placebo
findings contrast with the effacement of splenic architectureand drug-treated mice for each of the three trials demonstrated
observed in placebo mice due to marked expansion of red pulpthat CT53518 prolonged survival with p values of 0.001,
comprised of maturing myeloid cells and scattered admixed0.00005, and 0.0007 for trials 1, 2, and 3, respectively, using a
megakaryocytes (Figure 6E, iii and iv). The spleen displayedlog rank analysis. A combined Kaplan-Meier plot with the data
characteristic features of a myeloproliferative disorder withfrom trials 1–3 is shown in Figure 5D.
marked hypercellularity and myeloid hyperplasia consisting pre-Analysis of spleen weight and WBC counts from trial animals
dominantly of mature granulocytic elements (Figure 6E, iv).(Table 3) showed that in each of the three trials, the majority of
The immunophenotype of single-cell suspensions from theplacebo animals developed characteristic features of FLT3-ITD-
spleens of five placebo and five CT53518-treated animals frominduced myeloproliferative disease, while the majority of CT53518-
treated mice did not. The median spleen weight was 563 mg trial 1 (Table 4) was examined using myeloid markers Gr-1 and
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Figure 5. CT53518 increases survival in a murine
BMT model of FLT3-ITD myeloproliferative disease
A–C: Mice transplanted with bone marrow trans-
duced with Flt3-ITD/51 treated with placebo (n
35) or with CT53518 at 120 mg/kg/day (n  33).
No mice were censored in this analysis. The per-
centage of surviving mice (y axis) is plotted with
respect to time in days (x axis). The p value was
obtained using the log rank test for binary out-
come of dead or alive at the trial endpoint.
A: Trial 1, drug administered from day 32.
B: Trial 2, drug administered from day 25.
C: Trial 3, drug administered from day 25.
D: Combined data from trials 1–3.
E: Plasma concentration of CT53518 at different
time intervals after a single oral dose of 60 mg/
kg. Two or more mice at each time point were
analyzed and the data is plotted as ng/ml.
F: Plasma concentration of CT53518 observed in
drug-treated animals at trial endpoint. Plasma
was collected from seven animals at 2 hr, 6 hr,
and 12 hr after administration of the CT53518.
The background measurement was set to zero
in this graph and did not measure more than
5 ng.
Mac-1 to evaluate the proportion of myeloid cells present. These cDNA could be detected in the spleens of treated mice and the
disease was still polyclonal (data not shown).data showed that the placebo mice had an average of 60%
myeloid cells compared to an average of 14% in the drug-
treated group, which correspond closely to the peripheral blood Discussion
differentials from these animals. Control irradiated and reconsti-
tuted mice typically display 10% Mac-1 myeloid cells in the An understanding of the genetic defects that are causally impli-
cated in carcinogenesis has led to targeted therapy for thespleen. Southern analysis indicated that traces of the FLT3-ITD
Table 3. White blood cell counts (WBC, 106 per ml) and spleen weights (SW, mg) for placebo and CT53518-treated mice at trial endpoint
Spleen Weight (mg) CBC-WBC ( 106/ml)
Placebo CT53518 Off Drug Placebo CT53518 Off Drug
Mean 562 251 658 31.3 20.0 36.9
Median 563 189 595 23.0 4.3 33.8
Range 118–850 57–750 464–881 2.0–89.0 1.1–198 8.3–63.2
n 35 23 6 28 15 5
The mean and median values, range, and the number of animals (n) is listed. Placebo and CT53518 from all three trials are listed in the first two columns,
and the third column reflects data from healthy mice taken off drug treatment at trial endpoint and sacrificed at 30 days later (trial 2) or at time of
development of disease (trial 3).
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Figure 6. Response of white blood cells (WBC)
and differential counts to CT53518 in peripheral
blood
A and B: White blood cell counts from peripheral
blood collected by retroorbital sampling, plotted
as 106 white blood cells per ml over time. Onset
of drug therapy (A) or placebo (B) is indicated
by an arrowhead.
C: The average white blood cell differential
counts from the peripheral blood of placebo
(n  13), drug-treated (n  5), or wild-type
BALB/c (n  4) mice at trial endpoint are shown.
The numbers are plotted to reflect the relative
proportions of polymorphic neutrophils (PMN),
lymphocytes (L), and other cells (Other), which
includes monocytes, eosinophils, and basophils.
D: Kaplan-Meier plot of survival in off-drug ani-
mals. Mice transplanted with bone marrow trans-
duced with Flt3-ITD treated with placebo (n  9)
or with CT53518 at 120 mg/kg/day (n  6). Data
is included from trial 3 only, with drug being ad-
ministered from day 25 through day 65. The black
arrow indicates the point at which drug therapy
ceased. No mice were censored in this analysis.
The percentage of surviving mice (y axis) is plot-
ted with respect to time in days (x axis).
E: Histopathology of the spleen, sections stained
with hematoxylin and eosin, for drug-treated 10
(i) and 50 (ii) or placebo mice 10 (iii) and
50 (iv). For description, see text.
treatment of CML and gastrointestinal stromal tumors (GIST) et al., 2001; Yokota et al., 1997). FLT3 is an attractive therapeutic
target because of its high frequency in AML and because itthat harbor gain-of-function mutations in the c-Abl or c-Kit tyro-
sine kinases, respectively (Buchdunger et al., 2000; Carroll et confers a poor prognosis (Abu-Duhier et al., 2000; Kiyoi et al.,
1999; Kottaridis et al., 2001). CT53518, a novel piperazinyl quan-al., 1997; Druker and Lydon, 2000; Druker et al., 2001a, 2001b;
Joensuu et al., 2001; Mauro and Druker, 2001; Savage and azoline, is a potent and selective antagonist of FLT3 and the
closely related c-Kit and PDGFR. CT53518 treatment inhibitedAntman, 2002; Talpaz et al., 2002). A similar kinase inhibitor
strategy may be effective for treatment of AML patients that FLT3-ITD autophosphorylation and factor-independent cell
growth with an IC50 of 10–100 nM. CT53518 treatment of AMLhave a FLT3 kinase gain-of-function mutations (Abu-Duhier et
al., 2001; Kiyoi et al., 1999; Kottaridis et al., 2001; Nakao et al., cell lines that harbor an endogenous FLT3-ITD induced apo-
ptotic cell death, suggesting that FLT3 inhibitors might have1996; Rombouts et al., 2000; Whitman et al., 2001; Yamamoto
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Table 4. Immunophenotype of cells from the spleen of placebo or drug-treated mice, documenting percentage of myeloid cells
Mouse ID Mac-1, Gr-1 Mac-1, Gr-1 Total Mac-1
Placebo 403 43.9 12.1 55.9
Placebo 404 43.3 11.6 54.8
Placebo 405 60.0 14.5 74.5
Placebo 406 57.8 11.0 68.8
Placebo 412 35.0 11.2 46.2
Average 47.9 12.1 60.0
CT53518 418 2.5 2.5 5.0
CT53518 419 31.8 8.7 40.4
CT53518 426 8.3 2.7 11.0
CT53518 427 4.4 1.9 6.3
CT53518 429 2.1 1.9 7.0
Average 10.4 3.5 14.0
Cells from five mice of each group were stained with APC-conjugated anti-Gr-1 and PE-conjugated Mac-1, or PE-Mac-1 alone. The cells were gated for
live cells based on forward and side scatter profiles (MM). The percentage of Mac-1, Gr-1 double-positive cells, the additional percentage of Mac-1
single-positive cells, and the total percentage of myeloid cells in each of the mice is listed.
efficacy in treatment of FLT3-ITD-positive AML blasts. The po- for constitutive activation of the RAS/MAP kinase and PI3/Akt
kinase pathways.tential clinical application of CT53518 for the treatment of AML
was further validated using mouse models of FLT3-ITD-medi- In summary, we have developed CT53518, a potent and
specific FLT3 kinase inhibitor for the treatment of FLT3-ITD-ated AML in which CT53518 treatment resulted in a significant
decrease in disease progression and an increase in survival, positive AML. This drug has been developed specifically for the
purpose of treating AML associated with activating mutationsconfirming orally bioavailability and activity in vivo.
The AML cell line, MOLM 14, in which the FLT3-ITD mutation in FLT3. CT53518 is well suited for these purposes based on
preclinical studies in animals where it has high oral bioavailabil-plays an essential role in cell proliferation and survival, provides
a model system to characterize critical downstream effectors ity, a long plasma half-life, a good safety profile with chronic
administration, and efficacy in a mouse model of FLT3-ITD-of FLT3 signal transduction in AML. Although studies on the
mechanism of signal transduction by FLT3 are limited, signaling mediated disease in primary hematopoietic cells. Further sup-
port for this strategy is provided by the observation thatby the other type III RTKs, especially the PDGFR, has been
studied extensively (Blume-Jensen and Hunter, 2001; Heldin CT53518 induces apoptosis of FLT3-ITD-positive AML cells, a
result similar to that observed when BCR/ABL-positive leukemiaand Westermark, 1999). PDGFR autophosphorylation creates
docking sites for interaction with a number of signaling or adap- cells are treated with STI571 (Beran et al., 1998, Fang et al.,
2000; Oetzel et al., 2000). It is thus quite possible that CT53518,tor proteins including the p85 subunit of PI-3 kinase, PLC
, Src,
STAT 5, Shc, Grb2, and Grb7 (Blume-Jensen and Hunter, 2001; or other classes of FLT3 inhibitors, will have clinical utility in
treatment of AML. The ultimate success of this therapeutic strat-Heldin and Westermark, 1999). The sites of tyrosine autophos-
phorylation for FLT3 have not been determined, but a phosphor- egy now awaits the outcome of clinical trials that are underway
to evaluate the efficacy of CT53518 for the treatment of AML.ylation-dependent interaction with Grb2, Src family members,
PLC
, and Shc has been reported. (Dosil et al., 1993; Marchetto However, based on recent reports of efficacy of STI571 in treat-
ment of CML blast crisis and the comparable effects of CT53518et al., 1999; Zhang et al., 1999). A direct interaction with signaling
in this preclinical analysis, CT53518 shows great promise formolecules has not been reported for FLT3-ITDs, but their ex-
treating this poor prognostic group of AML patients.pression in IL-3-dependent hematopoietic cell lines results in
the phosphorylation of STAT, Shc, Jak 2, Cbl, Erk, and Akt
Experimental procedures(Hayakawa et al., 2000; Lavagna-Sevenier et al., 1998; Mizuki
et al., 2000; Rottapel et al., 1994; Tse et al., 2000). These studies
Kinase assays for CT53518 specificity analysis
indicate that FLT3-ITDs mediate sustained activation of the All receptor tyrosine kinase assays were cell based and have been described
STAT, RAS/MAP kinase, and PI3 kinase pathways that are previously (Yu et al., 2001) except for the insulin receptor (InsR) kinase
assay, which was an enzyme-based assay measuring phosphorylation ofknown to play a role in hematopoietic cell transformation (Be-
the histone H2b substrate (GIBCO-BRL, Gaithursburg, MD). Briefly, 500 ngnekli et al., 2002; Birkenkamp et al., 2001; Schuringa et al.,
of purified recombinant InsR (Calbiochem, San Diego, CA) was incubated2000; Towatari et al., 1997; Rodriguez-Viciana et al., 1994; Testa
with a 20 l reaction mixture containing 25 mM HEPES (pH 8), 25 mM MgCl2,and Bellacosa, 2001; Zhou et al., 2001).
25 mM -glycerophosphate, 2 mM DTT, 100 M Na3VO4, 10 M ATP, 5
Based on these considerations, we investigated the role of Ci of [
-33P]ATP, and 5 g of histone H2b in the presence or absence of
FLT3-ITD in RAS/MAP kinase pathway activation in Molm-14 30 M CT53518 at 30C for 30 min. Samples were subjected to SDS-PAGE,
and substrate phosphorylation was detected by autoradiography.cells by monitoring Erk2 phosphorylation. A high level of consti-
All nonreceptor tyrosine kinases, serine/threonine kinases, MAP kinases,tutive Erk2 phosphorylation was observed in Molm-14 and in
and MAPK kinases assays were enzyme-based assays and were describedFLT3-ITD-negative THP-1 cells. However, treatment with
previously (Yu et al., 2001) except that of the Abl kinase assay, for whichCT53518 only blocks Erk2 phosphorylation in FLT3-ITD-positive
phosphorylation of a specific peptide-EAIYAAPFAKKK substrate was used
Molm-14 cells. Similarly, CT53518 selectively blocked Akt phos- (Dorsey et al., 2000). Abl kinase reaction was performed by incubating 2 ng
phorylation in FLT3-ITD-positive AML cells. This study indicates of purified bacterially expressed Abl tyrosine kinase (Calbiochem) with 50
l of reaction mixture containing 25 mM HEPES (pH 8), 25 mM MgCl2, 2that in AML cell lines, FLT3-ITD may be the sole mechanism
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mM DTT, 10 M ATP, 5 Ci of [
-33P]ATP, and 100 M peptide substrate Transplant model
at 30C for 10 min in the presence of various concentrations of CT53518 Bone marrow transplantation assays with 1 106–3 106 cells were carried
(0.01–30 M), and the reaction was terminated by the addition of 50 l of out as described previously (Schwaller et al., 1998; Liu et al., 2000; Kelly et
1.5% ice-cold phosphoric acid. The quenched assay solution was trans- al., 2002).
ferred to a phosphocellulose membrane microplate (Millipore Corporation, Any animals with splenomegaly (spleen boundary detectable at the
Bedford, MA), which was subsequently washed and counted on a scintillation dorsal midline) or that were moribund were sacrificed and analyzed for signs
counter as described (Yu et al., 2001). of MPD.
Peripheral blood was collected from the retroorbital cavity using a hepa-
Cell culture and growth curves rinized glass capillary. Blood smears were stained with Wright and Giemsa.
Ba/F3 cells were maintained in RPMI, 10% FCS, and IL-3 (0.5 ng/ml, R&D Manual and automated (ADIVA 120 Hematology system, Bayer) total and
Systems, Minneapolis, MN). Retroviral stocks were generated using MSCV differential blood cell counts were performed. Histopathologic exam of rele-
constructs FLT3-ITD (Kelly et al., 2002), TEL/TRKc (Liu et al., 2000), TEL/ vant organs (spleen, liver, heart, lungs, intestine, hindlimb bones, and kid-
PDGFR (Tomasson et al., 1999), and BCR/ABL (Daley et al., 1990) as neys) and preparation of single-cell suspensions from spleen and bone
described previously (Kelly et al., 2002; Schwaller et al., 1998). Retrovirally marrow for flow cytometry was performed as described (Schwaller et al.,
transduced Ba/F3 cells were cultured for 48 hr and selected with G418 for 1998; Liu et al., 2000; Kelly et al., 2002). In each trial, mice were dosed with
14 days and cultured in media without IL-3 to confirm factor-independent either drug or placebo. Assuming that 20% of drug-treated animals and
growth. 80% of untreated animals would develop an MPD, we designed our trial to
Molm-13 and Molm-14 cell lines of AML-M5a class were obtained from have 80% power to detect this difference at the 0.05% significance level
Fujisaki Cell Center (Okayama, Japan) and were cultured in RPMI 1640 using 11 mice. In comparing the survival time of the mice, all times are
supplemented with 10% FBS. AML cell lines HL60 (AML-M3) and AML193 measured from the day of BMT, and the log rank test is used to attach a
(AML-M5), KG-1, KG-1a, THP-1, and ALL cell line RS4;11 were purchased significance level to the difference in the survival curves. Mice alive at the
from ATCC (Bethesda, MD) and were cultured according to supplier’s speci- end of the study or that were sacrificed in an apparently healthy condition
fications. Cells (initial count of 0.3  105–1.0  105 ) were washed three at the end of the study were considered censored in this analysis.
times in RPMI 1640 medium and plated in 1 ml of complete growth media
(without IL-3 for the Ba/F3 cells) in the presence of increasing concentrations Acknowledgments
of CT53518 (0.004–30 M). Cells were grown for 3–7 days in tissue culture,
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Fluorescein isothiocyanate (FITC)-conjugated annexin V (Becton Dickson
Biosciences, San Diego, CA) binding to phospholipid phosphatidylserine References
was used to evaluate CT53518-induced cell apoptosis using flow cytometry
techniques. AML cells were plated at 2.5  105 per well in 24-well plates in
Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Gari, M.A., Peake, I.R., Rees,
growth medium with 1 M of CT53518. At daily intervals, cells were har-
D.C., Vandenberghe, E.A., Winship, P.R., and Reilly, J.T. (2000). FLT3 internal
vested, washed, and resuspended in 100 l binding buffer containing 10 tandem duplication mutations in adult acute myeloid leukaemia define a
mM HEPES (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl2. Annexin V-FITC high-risk group. Br. J. Haematol. 111, 190–195.
(100 ng) and propidium iodide (250 ng) were added to the cell suspension
Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R., andfollowed by incubation at room temperature for 15 min. Flow cytometry was
Reilly, J.T. (2001). Identification of novel FLT-3 Asp835 mutations in adultperformed immediately after staining on a FACSort flow cytometer (Becton
acute myeloid leukaemia. Br. J. Haematol. 113, 983–988.Dickson) with excitation at 488 nm. Fluorescence of annexin V-FITC and
DNA propidium iodide staining were measured at 515 nm and 585 nm, Benekli, M., Xia, Z., Donohue, K.A., Ford, L.A., Pixley, L.A., Baer, M.R.,
respectively. Baumann, H., and Wetzler, M. (2002). Constitutive activity of signal trans-
ducer and activator of transcription 3 protein in acute myeloid leukemia
Drug preparation and administration blasts is associated with short disease-free survival. Blood 99, 252–257.
CT53518 was prepared as a powder and stored at 4C and resuspended
Beran, M., Cao, X., Estrov, Z., Jeha, S., Jin, G., O’Brien, S., Talpaz, M.,in a 0.5% methylcellulose (MC) in water solution prior to use. Dosing of drug
Arlinghaus, R.B., Lydon, N.B., and Kantarjian, H. (1998). Selective inhibition(40–120 mg/kg/day) or placebo (MC only) was performed every 12 hr by
of cell proliferation and BCR-ABL phosphorylation in acute lymphoblasticgavage (100l) using 22-gauge needles (Hornbecks). Plasma concentrations
leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinaseof the drug were calculated by mass spectrometry using 50 l of plasma.
inhibitor (CGP-57148). Clin. Cancer Res. 4, 1661–1672.
Ba/F3 FLT3-ITD nude mice xenograft leukemia model Birkenkamp, K.U., Geugien, M., Lemmink, H.H., Kruijer, W., and Vellenga,
Athymic nude mice (n  10 for each CT53518-treated or vehicle control E. (2001). Regulation of constitutive STAT5 phosphorylation in acute myeloid
group) were each injected via marginal tail vein with 1  106 Ba/F3 cells leukemia blasts. Leukemia 15, 1923–1931.
expressing W51 FLT3-ITD mutant. Mice were not dosed in the first week to
Blume-Jensen, P., and Hunter, T. (2001). Oncogenic kinase signalling. Natureallow FLT3-ITD-expressing cells to initiate disease. In the second study, an
411, 355–365.extra group of mice were orally dosed BID at 20 mg/kg of CT53518. Dosing
continued until day 42 or day 57 in the two studies. For statistical analysis, Buchdunger, E., Cioffi, C.L., Law, N., Stover, D., Ohno-Jones, S., Druker,
a log-rank test was used to compare the difference between vehicle- and B.J., and Lydon, N.B. (2000). Abl protein-tyrosine kinase inhibitor STI571
CT53518-treated groups. Differences were statistically significant at p  inhibits in vitro signal transduction mediated by c-kit and platelet-derived
growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139–145.0.05.
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